Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07545174
Starting soon Not applicable

Role of the Environment in Pediatric Obesity

NCT07545174 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Tours
Phase
Not applicable
Started
2026-06
Last updated
2026-04-22

Condition(s) studied

Obesity (Disorder)

Investigational drug(s) / intervention(s)

Blood testUrine sampleHair sample

Blood test: Inclusion visit: during the routine blood test, one additional tube of blood will be collected for the study.

Urine sample: Inclusion visit: a urine sample will be collected for the study.

Hair sample: Inclusion visit: a hair sample will be taken from the patient.

Study summary

Childhood obesity is a particular concern in developed countries such as the United States, the United Kingdom, Canada, and certain European countries. According to the World Health Organization (WHO), approximately 6% of children under the age of 5 worldwide were obese in 2016, a figure that continues to rise.

The pathophysiology of pediatric obesity can be explained by several interconnected biological and behavioral mechanisms. In particular, it involves dysfunctions in the hormones that regulate appetite and satiety, as well as dysfunctions in lipid metabolism.

Per- and polyfluoroalkyl substances (PFAS) are a large family of synthetic chemical compounds. The main PFAS are perfluorooctanoic acid (PFOA), perfluorooctanesulfonic acid (PFOS), perfluorononanoic acid (PFNA), and perfluorohexanesulfonic acid (PFHxS). PFAS are present in many everyday consumer products.

Bisphenol A (BPA) is a chemical compound used primarily in the manufacture of plastics and resins. It is commonly found in polycarbonate plastics, used to make food containers and water bottles, as well as in epoxy resins, which are used to coat the inside of food cans and water pipes.

Non-persistent pesticides, such as organophosphates and polychlorinated biphenyls, are chemicals used primarily in agriculture to control insects and other pests.

There are arguments suggesting that PFAS, bisphenol A, and non-persistent pesticides may play a role in the onset of pediatric obesity, particularly by acting.

Eligibility

Sex
ALL
Min age
6 Years
Max age
15 Years
Healthy volunteers
Accepted
Inclusion Criteria: Patient with Obesity disorder : * Children with obesity (according to the BMI curves of the International Obesity Task Force/IOTF) * Follow-up within the obesity network of the Centre Val de Loire region (ObeCentre) Control group: * Children who are not obese (according to the BMI curves of the International Obesity Task Force/IOTF) All: * Children aged 6 to 15 at the time of inclusion (inclusive) * Whose two parents, or legal guardian, have signed an informed consent form * Patients affiliated with or covered by a social security system Exclusion Criteria: * Disorder preventing understanding of trial information or informed consent.

Primary outcome measure(s)

  • PFOA concentration — At the enrollment visit
    Difference in plasma PFOA concentration measured in ng/mL between obese and non-obese children (control group). PFOA will be measured in plasma using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) at the Laberca laboratory.

Trial sites (2)

FacilityCityRegionStatus
CHRU de Tours Tours France
CHRU de Tours Tours France

More University Hospital, Tours trials in France

Communication Enhancement Among Ventilated Patients in Intensive Care Recruiting
Social Information Processing in Children: an ocUlo-pupillometric Tool for Standard Evaluation Recruiting
Assessment and Follow-up of Surgical Treatment of Hemivertebra in Children Recruiting
Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea Recruiting
Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial Recruiting

Other trials for the same condition

Hormonal and Microbiota Modulation After Endoscopic Sleeve Gastroplasty Starting soon
Impact of a Pro-diversity Gut Microbiota Diet After a Bariatric Surgery on Gut Microbiota, Eating Behaviour and Sensory Function Recruiting
Dramatherapy for Psychological and Social Well-Being in Obesity and Bariatric Care Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07545174 on ClinicalTrials.gov ↗ ← All trials in France